on Sandoz Group AG (isin : CH1243598427)
Sandoz and Regeneron Resolve Patent Dispute
Sandoz Group AG has announced a settlement with Regeneron Pharmaceuticals, effectively resolving all patent litigation related to the US aflibercept biosimilar. This agreement facilitates the launch of Enzeevu™, Sandoz's FDA-approved biosimilar to Eylea®, expected by the end of 2026. The launch aims to strengthen Sandoz's position in the US biosimilar market.
The legal dispute, initiated by Regeneron in August 2024 under the BPCIA, involved up to 46 patents. The resolution allows Sandoz to enter the market potentially earlier than the fourth quarter of 2026. Enzeevu™, approved in 2024, is designed to treat neovascular age-related macular degeneration by improving visual acuity.
Sandoz's strategy focuses on expanding its biosimilar portfolio to offer cost-effective medicines, with Enzeevu™ marking a significant step in this direction, providing patients with increased access to affordable treatment options.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Sandoz Group AG news